Welcome to our dedicated page for Steris Plc news (Ticker: STE), a resource for investors and traders seeking the latest updates and insights on Steris Plc stock.
News and updates about STERIS plc (NYSE: STE) focus on its role as a medical technology company that supports patient care with an emphasis on infection prevention. The company regularly issues press releases from Dublin, Ireland, describing its financial performance, dividends, leadership changes and investor events, giving readers insight into how its healthcare and life science products and services business is developing.
Investors following STERIS news can expect recurring coverage of quarterly and annual financial results, where the company reports total revenue from continuing operations, segment performance for Healthcare, Applied Sterilization Technologies (AST) and Life Sciences, and both GAAP and non-GAAP metrics such as adjusted earnings per diluted share and free cash flow. These releases often include management commentary and an outlook for future fiscal periods, along with detailed explanations of non-GAAP measures.
STERIS news also includes announcements of quarterly dividends, with information on dividend amounts, payment dates and record dates. Some releases highlight the company’s history of dividend growth. Governance and leadership developments, such as transitions in the Chief Financial Officer role or changes to the Board of Directors, are disclosed through both press releases and related SEC filings, and are frequently summarized in the news flow.
In addition, STERIS routinely announces conference calls to discuss financial results, providing access details and replay information for investors and analysts. Each release typically contains a cautionary statement regarding forward-looking information and references to risk factors described in the company’s SEC filings. Readers who monitor this news stream can follow how STERIS communicates its financial performance, strategic outlook, shareholder returns and governance matters over time.
STERIS plc (NYSE: STE) announced it will host a conference call on November 7, 2024, at 9:00 a.m. ET to discuss its fiscal 2025 second quarter financial results. The company will release its financial results after market close on November 6, 2024. Investors can access the call through the company's website or by phone. A replay will be available from 12:00 p.m. ET on November 7, using access code 6859931.
STERIS plc (NYSE: STE) has announced its participation in the Morgan Stanley Healthcare Conference on September 4, 2024, in New York City. Dan Carestio, President and CEO of STERIS, will present at 1:50 p.m. Eastern Time.
The presentation will be simultaneously webcast and available for replay on STERIS's investor relations website at www.steris-ir.com. STERIS is a leading global provider of products and services supporting patient care, with a focus on infection prevention.
The company's mission is to help customers create a healthier and safer world by offering innovative healthcare and life sciences solutions globally. For further information, investors can contact Julie Winter, Vice President of Investor Relations and Corporate Communications.
STERIS plc (NYSE: STE) reported strong financial results for Q1 fiscal 2025. Total revenue from continuing operations increased 8% to $1.3 billion, with constant currency organic revenue growing 6%. As reported EPS from continuing operations rose to $1.41, while adjusted EPS increased to $2.03.
Healthcare revenue grew 10% to $901.2 million, driven by 23% growth in consumables and 14% in services. Applied Sterilization Technologies revenue increased 7% to $249.8 million. Life Sciences revenue decreased 2% to $128.5 million due to a divestiture.
The company reiterated its fiscal 2025 outlook, expecting 6.5-7.5% revenue growth and adjusted EPS of $9.05-$9.25. STERIS remains confident in delivering on its full-year guidance.
STERIS plc (NYSE: STE) has announced a 5.6% increase in its quarterly dividend to $0.57 per share, marking the company's 19th consecutive year of dividend growth. The dividend will be payable on September 20, 2024, to shareholders of record as of September 5, 2024. This represents a $0.05 increase from the previous dividend.
STERIS, a global leader in infection prevention products and services for healthcare and life sciences, continues to demonstrate its commitment to shareholder value through consistent dividend growth. The company's focus on creating a healthier and safer world through innovative solutions underscores its strong market position and financial stability.
STERIS plc (NYSE: STE) has announced it will host a conference call on August 7, 2024, at 9:00 a.m. ET to discuss its fiscal 2025 first quarter financial results. The call can be accessed via www.steris-ir.com or by phone. A press release detailing the financial results will be issued after the U.S. market closes on August 6, 2024. For those unable to attend the live call, a replay will be available from 12:00 p.m. ET on August 7, 2024, accessible through the company website or by phone using the access code 5644736. This announcement provides investors and analysts an opportunity to gain insights into STERIS's recent financial performance and future outlook.
An affiliate of Peak Rock Capital has completed the acquisition of HuFriedyGroup, the dental segment of STERIS plc (NYSE: STE). HuFriedyGroup, founded in 1908, is a global leader in dental instruments, infection prevention products, and instrument management systems. The company serves customers in approximately 100 countries and employs around 1,500 people across more than 20 global facilities. Peak Rock Capital sees this acquisition as a significant investment opportunity, aiming to drive new product innovation and organic growth. The firm also plans to support complementary acquisitions to expand the product and brand portfolio.
STERIS plc (NYSE: STE) announced financial results for its fiscal 2024 fourth quarter and full year, with total revenue up 12% to $5.5 billion. U.S. GAAP earnings per diluted share were $3.81, adjusted earnings per diluted share increased to $8.83. The company reported a targeted restructuring plan. Fourth quarter revenue increased 10% to $1.5 billion. Healthcare segment outperformed, with revenue growth primarily in the United States. Fiscal 2025 outlook includes mid-to-high single digit revenue growth and double-digit earnings growth.
STERIS plc (NYSE: STE) declared a quarterly interim dividend of $0.52 per share, payable on June 26, 2024. The Company focuses on infection prevention in healthcare and offers healthcare, life sciences, and dental products globally.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Steris Plc (STE)?
What is the market cap of Steris Plc (STE)?
